{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.6","upperLimit":"51.0","value":"33.3"},{"groupId":"OG001","lowerLimit":"28.7","upperLimit":"68.1","value":"48.1"},{"groupId":"OG002","lowerLimit":"18.7","upperLimit":"81.3","value":"50.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG005","lowerLimit":"51.8","upperLimit":"99.7","value":"88.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"Complete response rate is defined as percentage of participants achieving a best overall response of complete response.\n\nComplete response via PET-CT:\n\n* Lymph nodes/extralymphatic: Score 1, 2, 3a with/without residual mass on 5-point scale\n* New lesions: No\n* Bone marrow: No FDG-avid disease\n\nComplete response via CT scan:\n\n* Lymph nodes/extralymphatic: Target nodes/nodal masses ≤ 1.5 cm longest transverse diameter.\n* Nonmeasured lesion: None\n* New lesions: No\n* Bone marrow: Normal\n\nComplete response (CR) (Cohort 5):\n\n* Brain imaging: No contrast enhancement\n* Corticosteroid dose: None\n* Eye examination: Normal\n* Cerebrospinal fluid cytology: Negative\n\nComplete response unconfirmed (CRu) (Cohort 5):\n\n* Brain imaging: No contrast enhancement, Minimal abnormality\n* Corticosteroid dose: Any\n* Eye examination: Normal, minor RPE abnormality\n* Cerebrospinal fluid cytology: Negative","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"NUMBER","populationDescription":"All participants in the JCAR017 treated set.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)","title":"Complete Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}